|
市場調查報告書
生物武器防禦產業的未來：法規限制、資金投入、企業介紹
The Future of the Biodefense Industry: Regulation, funding opportunities & company profiles
|
生物武器防禦產業的未來：法規限制、資金投入、企業介紹 是由出版商Business Insights在2009年09月所出版的。
這份英文市場調查報告書包含183 pages 價格從美金3835起跳。
自從2001年多起恐怖攻擊事件發生後出現SARS郵件攻擊事件，生物武器相關防禦產業便逐漸發展。美國在2001年∼2009年間投入500億美元的資金發展該產業。
本報告書內容包括：目前生物兵器防禦產業的動向、生物攻擊事件引發疾病的相關對策及治療藥品研發、生產活動動向分析、政府方針及行動、未來動向等。內容綱要摘記如下：
實施概要
第1章 現況分析
- 摘要
- 介紹
- 生物兵器在戰爭・恐怖攻擊事件中的利用
- 生物恐怖攻擊：威脅的範圍及性質
- 將來的威脅
第2章 法規限制環境
第3章 主要病原菌
- 摘要
- 介紹
- 炭疽病
- 瘟疫
- 兔熱病
- 天花
- 病毒性出血熱
- 肉毒桿菌中毒症
- 蓖麻毒素
- 金黃色葡萄球菌
- 布魯氏桿菌
- 鼻疽
- 類鼻疽
- Q熱
- 結論
第4章 生物防禦基金
第5章 企業介紹
- 摘要
- 介紹
- 美國
- 加拿大
- 英國
- 丹麥
- 澳洲
- 印度
- 中國
- 以色列
- 結論
第6章 未來預測
- 摘要
- 介紹
- 美國的資金投入：現實
- 歐洲是否充分發揮其功能？
- 合作不足
- 其他研究費用
- 生物安全保障的問題點
- 解決潛在需求
第7章 附錄
圖表
Abstract
The major contemporary bioterrorist event which has opened up programs of
research and development (R&D) in pharmaceutical countermeasures and
treatments was the anthrax mail attacks which occurred only weeks after the
9/11 atrocities, in October 2001. The mailings killed five people and exposed
hundreds more - with thousands of US citizens seeking prophylactic
antibiotics. Since then the biodefense industry has grown massively, with the
US releasing around $50bn in biodefense funding in 2001-2009. Other
international bodies, such as the EU, have also increased their vigilance and
research efforts. This report sets out to describe and analyze the work of the
biodefense industry in terms of past, present and future pharmaceutical
research, development and production to counter or treat diseases caused by
biological attack. It also describes government policies and initiatives in
several countries which have spurred research and production in pharmaceutical
countermeasures and treatments for such diseases and will examine the various
factors which influence those policies and the market, including current and
future threats and how the industry is responding to new discoveries.
Table of Contents
Executive summary
- Setting the scene
- Regulatory environment
- Major pathogens for BW
- Biodefense funding
- Company profiles
- Future perspectives
Chapter 1 Setting the scene
- Summary
- Introduction
- The use of biological agents in warfare and terrorism
- Warfare
- Offensive BW programs
- Bioterrorism: Extent and nature of the threat
- Creation
- Bulk manufacture
- Weaponization
- Delivery
- Future threats
- Pre-2001 bioterrorism
- 2001 - September 11 and the anthrax attacks
Chapter 2 Regulatory environment
- Summary
- Introduction
- US bodies
- FDA
- Center for Biologics Evaluation and Research (CBER)
- Center for Drug Evaluation and Research (CDER)
- Office of Counterterrorism and Emerging Threats
- National Institutes of Health (NIH)
- The National Institute of Allergy and Infectious Diseases (NIAID)
- Biomedical Advanced Research and Development Authority (BARDA)
- Public Health Emergency Medical Countermeasures Enterprise (PHEMCE)
- Project Bioshield
- Centers for Disease Control and Prevention (CDC)
- US Army Medical Materiel Development Activity (USAMMDA)
- European bodies
- European Commission
- European Council Health Security Committee
- European Centre for Disease Prevention and Control (ECDC)
- The European Medicines Agency (EMEA)
- Economic Commission for Europe
- Joint Commission/Pharmaceutical Industry Task Force
- 2009-2011 Indicative Program for the Instrument for Stability
- International Agencies
- World Health Organisation (WHO)
- United Nations
- Global Health Security Initiative (GHSI)
Chapter 3 Major pathogens for BW
- Summary
- Introduction
- Anthrax
- Developmental therapeutics and vaccines
- Plague
- Developmental therapeutics and vaccines
- Tularemia
- Developmental therapeutics and vaccines
- Smallpox
- Developmental therapeutics and vaccines
- Viral Hemorrhagic Fevers - Ebola, Marburg, Crimean-Congo, Hantavirus, Lassa
- Developmental therapeutics and vaccines
- Botulism
- Developmental therapeutics and vaccines
- Ricin
- Developmental therapeutics and vaccines
- Staphylococcal enterotoxins
- Developmental therapeutics and vaccines
- Brucella group
- Developmental therapeutics and vaccines
- Glanders
- Developmental therapeutics and vaccines
- Melioidosis (Whitmore' s disease)
- Developmental therapeutics and vaccines
- Q fever
- Developmental therapeutics and vaccines
- Conclusion
Chapter 4 Biodefense funding
- Summary
- US funding
- Department of Health and Human Services (HHS)
- Biomedical Research and Development Authority (BARDA)
- Department of Homeland Security (DHS)
- Other departments
- Grants available for biodefense R&D in the US
- NIH Challenge grants in health & science research
- NIH Cooperative Research & Development Agreement (CRADA)
- Small business awards
- NIH small business biodefense program awards
- Project BioShield awards
- Regional Centers of Excellence for Biodefense and Emerging
- Infectious Diseases (RCE)
- Defense Threat Reduction Agency (DTRA)
- US Army Medical Research Institute of Infectious Diseases (USAMRIID)
- Technology transfer
- Defense Advanced Research Projects Agency (DARPA)
- European funding
- United Kingdom
- France
- Germany
- EU biodefense programs
- European Defense Agency (EDA)
- EDA' s Joint R&D Investment Program
- Bio-Edep
- Bioterrorism Research Resilience Reaction (BIO3R)
- Biodefense industry
- New and Emerging Science and Technology (NEST)
- Health Protection Agency (HPA)
- Defense Science and Technology Laboratory (Dstl)
Chapter 5 Company profiles
- US
- Achaogen
- Contracts
- Advanced Life Sciences
- Contracts
- Alnylam Pharmaceuticals
- Contracts
- Cleveland BioLabs
- Contracts
- Dynavax Technologies Inc.
- Contracts
- Dynport Vaccine Company Llc (DVC)
- Contracts
- Elusys Therapeutics
- Contracts
- Emergent BioSolutions
- Contracts
- Ichor Medical Systems
- Contracts
- Nanotherapeutics
- Contracts
- Peregrine Pharmaceuticals, Inc.
- Contracts
- PharmAthene
- Contracts
- SIGA Technologies
- Contracts
- VaxGen
- Contracts
- XOMA
- Contracts
- Canada
- Affinium Pharmaceuticals
- Contracts
- Cangene
- Contracts
- ID Biomedical Corporation
- Contracts
- UK
- Acambis
- Contracts
- Cambridge Biostability (CBL)
- Contracts
- MNLpharma
- Contracts
- Denmark
- Bavarian Nordic
- Contracts
- Australia
- Vaxine Pty
- Contracts
- India
- Panacea Biotec Ltd.
- Contracts
- China
- Sinovac Biotech Ltd.
- Conclusion
- Biodefense products: the risks
Chapter 6 Future perspectives
- Summary
- Introduction
- Assessing future threats
- GM technology
- Synthetic biology
- US funding - the reality
- Has the US got value for its £50 billion-worth of funding since 2001?
- Potential biodefense business
- Getting a grant in the US
- Project Bioshield
- Is Europe doing enough?
- Lack of coordination
- US
- EU
- Biodefense - at the expense of other research?
- Mismanagement of the stockpile
- Case study: VaxGen
- Problems of biosecurity
- US
- Russia and the FSU
- Fulfilling unmet needs
Chapter 7 Appendix
- CDC characterization of biological threats
- Glossary
- Index
List of Figures
- Figure 1.1: Bioterrorism incidents 1970-2008
- Figure 2.1: US biodefense funding by department 2001-09
- Figure 3.1: R&D funding pathway for biodefense medical countermeasures
- Figure 4.1: Project BioShield procurement process
- Figure 4.5: US biodefense funding ($m), 2001-12
- Figure 4.6: BARDA funding forecasts ($m), 2009-14
- Figure 5.7: Cleveland BioLabs research spending on Protectan CBL502 for
biodefense applications ($m), 2008-09
- Figure 5.8: Emergent BioSolutions operating results ($m), 2008-09
- Figure 5.9: PharmAthene financial results ($m), 2008-09
- Figure 5.10: Cangene financial results ($m), 2004-08
- Figure 5.11: Bavarian Nordic financials (DKKm), 2004-08
- Figure 6.12: US biodefense funding ($m), 2001-09
- Figure 6.13: VaxGen financials ($m), 2005-08
- Figure 6.14: NIH funded biocontainment laboratories
- Figure 7.15: CDC characterization of biological threats
List of Tables
- Table 2.1: US biodefense presidential acts
- Table 2.2: US biodefense acts post-2001
- Table 2.3: European Biodefense Legislation
- Table 3.4: Developmental therapeutics and vaccines for anthrax
- Table 3.5: Developmental therapeutics and vaccines for plague
- Table 3.6: Developmental therapeutics and vaccines for tularemia
- Table 3.7: Developmental therapeutics and vaccines for smallpox
- Table 3.8: Developmental therapeutics and vaccines for VHF
- Table 3.9: Developmental therapeutics and vaccines for botulism
- Table 3.10: Developmental therapeutics and vaccines for ricin
- Table 3.11: Developmental therapeutics and vaccines for staphylococcal
enterotoxins
- Table 3.12: Developmental therapeutics and vaccines for brucella
- Table 3.13: Developmental therapeutics and vaccines for glanders
- Table 3.14: Developmental therapeutics and vaccines for melioidosis
- Table 3.15: Developmental therapeutics and vaccines for Q fever
- Table 4.16: US biodefense funding by department ($m), 2001-10
|
